On 21 March 2026, multiple generic semaglutide products launched on the Indian market, proclaiming “Day 1 entry” on expiry of Novo Nordisk’s core Indian patent for semaglutide (Ozempic®/Wegovy®).
The products launched on the Indian market include:
- Dr Reddy’s injectable semaglutide, launched under the name Obeda™, in a pre-filled disposable pen for type 2 diabetes. According to Dr Reddy’s, it was the first Indian company to receive approval from the Drugs Controller General of India (DCGI) for generic semaglutide. The cost to the patient will be about INR 4,200 per month.
- Zydus Lifesciences’ Semaglyn™, Mashema™ and Alterme™. Zydus’ injectable semaglutide received DCGI approval for the treatment of both Type 2 diabetes mellitus and obesity. The products are available in a reusable, multi-dose pen device. The average monthly cost of the treatment will be approximately INR 2,200. Under an agreement announced on 17 March 2026, Lupin holds semi-exclusive rights to co-market Zydus’ semaglutide injection under the brand names Semanext® and Lupin’s Livarise®.
- Alkem Laboratories’ semaglutide injection, launched under the names Semasize™, Obesema™ and Hepaglide™. It is available in a pre-filled disposable injection pen at a price starting at INR 1,800 for a month’s dosage, which amounts to a weekly cost of about INR 450. A reusable pen option is also available. Alkem received DCGI approval for type 2 diabetes mellitus and chronic weight management as an adjunct to diet and exercise, subsequent to a review of its Phase 3 clinical trials conducted in India.
- Sun Pharma’s Noveltreat™ and Sematrinity™ (semaglutide), indicated for chronic weight management and type 2 diabetes mellitus, respectively. Noveltreat™ is available in a pre-filled pen, while Sematrinity™ is provided in a multi-dose pen format. Weekly therapy costs (from initiation to the highest dose) range from about INR 900 to 2,000 for Noveltreat™ and INR 750 to 1,300 for Senatrinity™.
- Glenmark Pharmaceuticals’ GLIPIQ®, for the management of Type 2 diabetes mellitus. The drug received DCGI approval in both vial and pre-filled pen formulations. The expected weekly cost of treatment with GLIPIQ® vials ranges from INR 325 to INR 440.
According to Indian-English language newspaper, The Hindu, the market for semaglutide in India is estimated to be $1 billion over the next two years, with an estimate of over 100 million people in India having diabetes and an additional 136 million being pre-diabetic.